Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

ican Federal Commission for the Protection against Sanitary Risk. ELAPRASE is now approved in 37 countries worldwide and sales for the year to December 31, 2007 were $181.8 million (2006: $23.6 million).

- In October 2007 ELAPRASE was launched in Japan, with sales and distribution managed by Genzyme Corporation. Shire's gross profit on the arrangement equates to an effective royalty of approximately 25% to 30%, but revenues will be recorded within product sales.

- REPLAGAL(R) - Fabry disease.

- REPLAGAL is now approved in 41 countries and sales for 2007 were up 22% to $143.9 million (2006: $117.7 million).

- In February 2007 REPLAGAL was launched in Japan through Shire's partner Dainippon Sumitomo Pharma Co., Ltd. Similar to ELAPRASE, Shire will record revenues within product sales.

Pipeline Highlights

Shire has expanded its product pipeline by in-licensing the following drug compounds and technologies in 2007:

- JUVISTA(R)

- In August 2007 Shire acquired exclusive rights to develop and commercialize JUVISTA worldwide (with the exception of EU member states) from Renovo Limited ("Renovo"). JUVISTA, which is being investigated for the prevention and reduction of scarring in connection with surgery, is in late Phase 2 development.

- Seven Phase 2 efficacy trials for JUVISTA have now been reported of which six demonstrated statistically significant efficacy. Phase 2 clinical trials in multiple other surgery types are ongoing and are expected to report during 2008 and 2009.

- Pharmacological chaperone compounds for Lysosomal Storage Disorders ("LSDs") - In November 2007 Shire in-licensed from Amicus Therapeutics, Inc. ("Amicus") the rights to three compounds in markets outside the US:

- AMIGAL(TM) for Fabry disease (Phase 2) received orphan drug designation by the EMEA, which may provide it with up to ten years market exclusivity in the EU;

- PLICERA(TM) for Gaucher disease (Phase 2) rec
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Columbia, MD (PRWEB) July 23, 2014 ... Station, an LC/MS amino acid analysis system developed ... analysis, the UF-Amino Station can analyze 38 amino ... , The UF-Amino Station achieves high-speed analysis utilizing ... spectrometer. The LCMS-2020 provides accurate analytical results even ...
(Date:7/23/2014)... July 23, 2014 StemGenex® , ... in the US aimed at improving the lives of ... clinical study for Parkinson’s disease. StemGenex believes that ... cell therapy are paramount when providing care to patients ... makes stem cell therapy accessible to the millions of ...
(Date:7/23/2014)... July 23, 2014 regulated information -- UCB today ... development pipeline with positive topline results from the ... study was designed to evaluate the efficacy and ... mg/day, without titration) compared to placebo, as adjunctive ... seizures, not fully controlled despite treatment with one ...
(Date:7/23/2014)... , July 23, 2014 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... Limited ("Cordlife"), a multi-product healthcare company catering to the mother and ... in assisting patients across the PRC, Singapore , ... India , the Philippines ...
Breaking Biology Technology:Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 2China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 3China Cord Blood Corporation and Cordlife Group Limited Announce Collaboration to Aid Asia-based Patients with Cord Blood Stem Cell Therapy 4
... Calif., March 20, 2012 Cepheid (NASDAQ: ... of Medicine and Dentistry of New Jersey (UMDNJ), it ... Health to develop sample processing and amplification methods for ... reaction (PCR) on the GeneXpert® System. The $1.3 million ...
... March 20, 2012 Heptares Therapeutics, the ... company of Shire PLC (LSE: SHP, NASDAQ: ... its exclusive option to license a novel adenosine A ... in preclinical development. Adenosine A 2A is a ...
... 19, 2012  MiMedx Group, Inc. (OTCBB: MDXG), an ... regenerative biomaterials and bioimplants processed from human amniotic ... distribution agreement with Systagenix, whereby Systagenix will co-market ... specifically processed from amniotic tissue, EpiFix® offers a ...
Cached Biology Technology:Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 2Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 3Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 4Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 2Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 3MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 2MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 3
(Date:7/23/2014)... strength, but it also holds the promise of a ... to convert sunlight into a clean, efficient alternative fuel. ... group using spinach to study the proteins involved in ... energy into carbohydrates used to power cellular processes. , ... efficient system ever built, capable of converting the energy ...
(Date:7/23/2014)... Migratory songbirds are disappearing, and though conservationists are examining ... habitat, acid rain and light pollution, a key piece ... birds go once they leave their breeding sites, and ... , To answer this question, a team of researchers ... migratory connectivity map produced for a songbird, using tracking ...
(Date:7/23/2014)... planet,s soil releases about 60 billion tons of carbon ... than that released by burning fossil fuels. This happens ... of carbon is balanced by carbon coming into the ... as well as by the underground activities of plant ... rising temperatures increase the rate of soil respiration. As ...
Breaking Biology News(10 mins):Spinach could lead to alternative energy more powerful than Popeye 2York University researchers use bird 'backpacks' to put wood thrushes migration on the map 2Climate change and the soil 2
... 2012) Aeras and the Infectious Disease Research Institute ... trial of IDRI,s novel tuberculosis vaccine candidate, ID93 + ... safety, tolerability and immunogenicity of the vaccine candidate in ... by Johnson County Clin-Trials in Lenexa, Kansas, in close ...
... has on pregnancy, are urging men to get ... development. Reproductive experts from the University of ... father,s obesity negatively impacts sperm, resulting in smaller ... While the health risks surrounding obesity ...
... Venture has developed a framework to evaluate the risk ... A paper based on this work: A framework for ... has been published in the Malaria Journal ... anti-infective drug, so it is important when developing new ...
Cached Biology News:As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing 2Thinking about kids? Man, you gotta shed the kilos 2MMV develops framework to assess risk of resistance for antimalarial compounds 2